iCAD downgraded to Hold from Buy at Laidlaw

Laidlaw analyst Yale Jen downgraded iCAD (ICAD) to Hold from Buy without a price target after the company announced it will be acquired by DeepHealth, a subsidiary of traded RadNet (RNDT). Although the valuation of the acquisition is “only modest,” it offers iCAD investors a more immediate investment exit under the current more turbulent macro investment environment, the analyst tells investors in a research note.